Cargando…
Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784059/ https://www.ncbi.nlm.nih.gov/pubmed/36550442 http://dx.doi.org/10.1186/s12885-022-10455-0 |
| _version_ | 1784857720822693888 |
|---|---|
| author | Allahyari, Abolghasem Ehsanpour, Ali Najafi, Behrouz Ansarinejad, Nafseh Mehrzad, Valiollah Kalantari, Behjat Raafat, Jahangir Ghadiany, Mojtaba Shahi, Farhad Gharib, Behrooz Moazed, Vahid Khosravi, Adnan Mirpour, Mir Hossein Salari, Sina Mortazavizadeh, Seyedmohammadreza Nekoyi, Amirabbas Khani, Mohsen Sadeghi, Alireza Gharib, Sirus Bary, Alireza Mirzania, Mehrzad Haghighat, Shirin Razavi, Seyed Mohsen Emami, Seyed Amir Hossein Hosseinzadeh, Mehran Mirbolouk, Mahdi Sadighi, Sanambar Shahrasbi, Abdolali Esfahani, Ali Gity, Masoumeh Anjidani, Nassim Kaf, Hamidreza Najaf, Safa |
| author_facet | Allahyari, Abolghasem Ehsanpour, Ali Najafi, Behrouz Ansarinejad, Nafseh Mehrzad, Valiollah Kalantari, Behjat Raafat, Jahangir Ghadiany, Mojtaba Shahi, Farhad Gharib, Behrooz Moazed, Vahid Khosravi, Adnan Mirpour, Mir Hossein Salari, Sina Mortazavizadeh, Seyedmohammadreza Nekoyi, Amirabbas Khani, Mohsen Sadeghi, Alireza Gharib, Sirus Bary, Alireza Mirzania, Mehrzad Haghighat, Shirin Razavi, Seyed Mohsen Emami, Seyed Amir Hossein Hosseinzadeh, Mehran Mirbolouk, Mahdi Sadighi, Sanambar Shahrasbi, Abdolali Esfahani, Ali Gity, Masoumeh Anjidani, Nassim Kaf, Hamidreza Najaf, Safa |
| author_sort | Allahyari, Abolghasem |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9784059 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97840592022-12-24 Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial Allahyari, Abolghasem Ehsanpour, Ali Najafi, Behrouz Ansarinejad, Nafseh Mehrzad, Valiollah Kalantari, Behjat Raafat, Jahangir Ghadiany, Mojtaba Shahi, Farhad Gharib, Behrooz Moazed, Vahid Khosravi, Adnan Mirpour, Mir Hossein Salari, Sina Mortazavizadeh, Seyedmohammadreza Nekoyi, Amirabbas Khani, Mohsen Sadeghi, Alireza Gharib, Sirus Bary, Alireza Mirzania, Mehrzad Haghighat, Shirin Razavi, Seyed Mohsen Emami, Seyed Amir Hossein Hosseinzadeh, Mehran Mirbolouk, Mahdi Sadighi, Sanambar Shahrasbi, Abdolali Esfahani, Ali Gity, Masoumeh Anjidani, Nassim Kaf, Hamidreza Najaf, Safa BMC Cancer Correction BioMed Central 2022-12-22 /pmc/articles/PMC9784059/ /pubmed/36550442 http://dx.doi.org/10.1186/s12885-022-10455-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Allahyari, Abolghasem Ehsanpour, Ali Najafi, Behrouz Ansarinejad, Nafseh Mehrzad, Valiollah Kalantari, Behjat Raafat, Jahangir Ghadiany, Mojtaba Shahi, Farhad Gharib, Behrooz Moazed, Vahid Khosravi, Adnan Mirpour, Mir Hossein Salari, Sina Mortazavizadeh, Seyedmohammadreza Nekoyi, Amirabbas Khani, Mohsen Sadeghi, Alireza Gharib, Sirus Bary, Alireza Mirzania, Mehrzad Haghighat, Shirin Razavi, Seyed Mohsen Emami, Seyed Amir Hossein Hosseinzadeh, Mehran Mirbolouk, Mahdi Sadighi, Sanambar Shahrasbi, Abdolali Esfahani, Ali Gity, Masoumeh Anjidani, Nassim Kaf, Hamidreza Najaf, Safa Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial |
| title | Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial |
| title_full | Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial |
| title_fullStr | Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial |
| title_full_unstemmed | Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial |
| title_short | Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial |
| title_sort | correction: comparing efficacy and safety of p013, a proposed pertuzumab biosimilar, with the reference product in her2-positive breast cancer patients: a randomized, phase iii, equivalency clinical trial |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784059/ https://www.ncbi.nlm.nih.gov/pubmed/36550442 http://dx.doi.org/10.1186/s12885-022-10455-0 |
| work_keys_str_mv | AT allahyariabolghasem correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT ehsanpourali correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT najafibehrouz correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT ansarinejadnafseh correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT mehrzadvaliollah correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT kalantaribehjat correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT raafatjahangir correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT ghadianymojtaba correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT shahifarhad correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT gharibbehrooz correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT moazedvahid correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT khosraviadnan correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT mirpourmirhossein correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT salarisina correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT mortazavizadehseyedmohammadreza correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT nekoyiamirabbas correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT khanimohsen correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT sadeghialireza correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT gharibsirus correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT baryalireza correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT mirzaniamehrzad correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT haghighatshirin correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT razaviseyedmohsen correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT emamiseyedamirhossein correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT hosseinzadehmehran correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT mirboloukmahdi correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT sadighisanambar correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT shahrasbiabdolali correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT esfahaniali correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT gitymasoumeh correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT anjidaninassim correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT kafhamidreza correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial AT najafsafa correctioncomparingefficacyandsafetyofp013aproposedpertuzumabbiosimilarwiththereferenceproductinher2positivebreastcancerpatientsarandomizedphaseiiiequivalencyclinicaltrial |